Amarin Corp Plc (AMRN)

[ziploc_1]

CBD...I agree your thinking about the benefits of Amarin's partnering with a large generic company for an AG of Vascepa in the US...

A generic company, which partners with Amarin on an AG of Vascepa in the US, could compete well on pricing to patients with the pricing to patients from other competing generic companies...which are also marketing a gV in the US at the same time ...and Amarin and Amarin's generic partner could benefit from the advantage of having greater purchasing power for their EPA from their manufacturers...due to the larger volumes of EPA, used to supply markets in Europe as well as in the US...This would lead to lead to lower prices for the supplies of EPA for Amarin and for its generic company partner...than the prices for the supplies of EPA for competing generic companies, which also need to also buy EPA from the same manufacturers.

At the same time, Amarin could continue with its sales of branded Vascepa in Europe...and Amarin could continue to benefit from lower prices for its EPA due to their higher volume purchases of EPA for the AG IN THE US and for their branded Vascepa IN EUROPE.